Skinvisible stock analysis
Skinvisible (SKVI) Stock Price & Analysis
SKVI Stock Chart & Stats
- Day’s Range
- $0.18 - $0.18
- 52-Week Range
- $0.15 - $0.54
- Previous Close
- $0.18
- Volume
- N/A
- Average Volume (3M)
- 258
- Market Cap
- $972.69K
- Enterprise Value
- $6.87T
- Total Cash (Recent Filing)
- $3,959
- Total Debt (Recent Filing)
- $5.72M
- Price to Earnings (P/E)
- ―
- Beta
- 0.21
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Skinvisible News
Skinvisible announces article on transdermal obesity formulation development
Skinvisible announced the publication of an article highlighting the Company’s innovative development of transdermal delivery of glucose-controlling agents using its proprietary delivery system Invisicare. The article, titled “Advancements in Transdermal
Skinvisible Inc unveils data on transdermal obesity formulations
Skinvisible Pharmaceutical announced data demonstrating its transdermal delivery of obesity drugs including a GLP-1 agonist and CB-1 receptor antagonist delivered by its proprietary Invisicare technology; a polymer delivery vehicle that
Skinvisible Inc expands obesity patent application for transdermal delivery
Skinvisible Pharmaceuticals announced the filing of a second patent application for its Invisicare technology and its transdermal delivery of obesity and glucose-controlling agents. This new application significantly broadens the scope
SKVI FAQ
What was Skinvisible’s price range in the past 12 months?
What is Skinvisible’s market cap?
When is Skinvisible’s upcoming earnings report date?
How were Skinvisible’s earnings last quarter?
Is Skinvisible overvalued?
Does Skinvisible pay dividends?
What is Skinvisible’s EPS estimate?
How many shares outstanding does Skinvisible have?
What happened to Skinvisible’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Skinvisible?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Skinvisible
Skinvisible, Inc., together with its associated entities, specializes in the creation, production, and distribution of advanced polymer-based delivery system technologies. These proprietary systems facilitate the topical, transdermal, and mucosal application of active ingredients, serving various sectors including pharmaceuticals (both prescription and over-the-counter), personal skincare, and cosmetics. Beyond dermatological applications, the company's non-dermatological formulations address specific needs in women's health, pain management, and other diverse markets. Under the 'Skinbrella' brand, Skinvisible provides consumer products such as sunless tanning lotions and sunscreens. Their business model also encompasses licensing these technologies to pharmaceutical and consumer goods companies. Furthermore, they assist pharmaceutical clients with early-stage formulation development. A key service involves reformulating existing pharmaceutical products nearing patent expiration, utilizing their unique Invisicare patent to introduce new product benefits and facilitate line extensions. Incorporated in 1998, the company originally operated as Microbial Solutions, Inc. before adopting the name Skinvisible, Inc. in February 1999. It maintains its headquarters in Las Vegas, Nevada.
- Sector
- Consumerdefensive
- Industry
- Medical - Pharmaceuticals
- CEO
- Terry H. Howlett
- Employees
- 2
- Website
- www.skinvisible.com
- Address
- 6320 South Sandhill Road, Las Vegas, NV, 89120, US
Skinvisible (SKVI) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 4 | 10 |
| Technical Analysis | 2 | 4 | 3 |
| Moving Averages | 5 | 0 | 7 |








